PubMed Health⌕ Search

Biomedical subjects

A T Lachand

Publications and source records attributed to A T Lachand.

At least 19 recordsLinked to original sources

[Surveillance and prognosis of "Ta" superficial tumors of the bladder. Homogeneous series of 138 cases followed for 1 to 18 years].

OBJECTIVE: To identify prognostic factors (risk of recurrence and risk of progression) and define the rules for the surveillance of stage Ta superficial bladder cancers, based on the follow-up of a homogeneous patient series. MATERIAL AND METHOD: 138 Ta bladder cancers were recruited from 1975 to 1995 and regularly followed by the same urologist. The follow-up was 1 to 18 years with a mean of 66 months and a median of 60 months. RESULTS: 30% of patients developed no recurrence (mean follow-up: 52 months). 70% developed one or several recurrences (mean follow-up: 80 months): 46% of Ta recurrences without progression and 24% of T > or = 1, with 10% of T > 1 recurrencesed. 13/138 patients died from bladder cancer, including 11 patients in less than 10 years. The risk of recurrence and the risk of progression were significantly correlated with: the macroscopic appearance of the cancer: size, number and extent of implantations, sessile or pedunculated nature, its site: slightly more serious on the fixed part of the organ, its clinical course assessed over the first 12 months: in patients without recurrence at 12 months: the risk of recurrence decreased from 70% to 35% the risk of deterioration decreased from 24% to 10%. However, this risk persisted in the long term: after more than 5 years without recurrence, 2 patients developed fatal recurrences, 11 and 15 years after the initial treatment. CONCLUSION: Although superficial, Ta bladder cancers are serious cancers. The risk of recurrence and progression justify close surveillance in the year following diagnosis. Subsequently, the frequency of follow-up can be adapted to the specific course of each case, but, regardless of these modalities, long-term (indefinite?) surveillance is recommended.

Adult↗

[Surveillance and prognosis of "T1" superficial tumors of the bladder. Homogeneous series of 88 cases followed for 1 to 22 years].

OBJECTIVE: Define the prognostic factors (risk of recurrence and risk of progression) and the rules for surveillance of stage T1 papillary bladder tumours based on the clinical course of a homogeneous patient series. MATERIAL AND METHOD: 88 T1 bladder tumours recruited from 1975 to 1995 and regularly followed by the same urologist. The follow-up ranged from 1 to 22 years with a mean of 52 months and a median of 48 months. RESULTS: 26% patients relapsed (mean follow-up: 71 months) 74% developed one or more recurrences (mean follow-up: 48 months) with recurrences staged > T1 in 35% of cases. 29/88 patients died from invasive bladder cancer, 14 before 3 years, 19 before 5 years, 28 before 10 years. The risk of recurrence and progression was statistically significantly related to the macroscopic appearance of the tumour; size, number and extent of implantations; its rate of progression assessed by the frequency of recurrence. In patients with no recurrence at 12 months, the risk of recurrence decreased from 74% to 50% and the risk of progression decreased from 35% to 20%. In this cohort, neither histological grading of the initial tumour, nor the degree of invasion of the submucosal lamina propria appeared to modify the prognosis. CONCLUSION: Stage T1 papillary bladder tumours, generally considered to be a superficial tumours regardless of their histological grade, have a serious prognosis and warrant close endoscopic surveillance during the year following the diagnosis. The subsequent frequency of follow-up can then be adapted to the specific mode of progression of each case, but, regardless of this mode of progression, the authors recommend long-term (life-long?) surveillance.

Adult↗

[[Neoadjuvant chemotherapy (cisplatin, doxorubicin, cyclophosphamide) in the treatment of invasive urothelial tumors of the bladder. Preliminary results of a prospective study concerning 22 patients].

Twenty two patients with transitional cell bladder carcinoma (T greater than or equal to 2 Mo) received 2 or 3 courses of systemic chemotherapy (cyclophosphamide 600 mg/m2, doxorubicin 60 mg/m2, cisplatinum 100 mg/m2) prior to total (18) or partial (18) cystectomy. Response rate was appreciated on the pathologic findings of the surgically removed bladders (pTNM): 5 tumor progression (23%); 8 tumor stability (36%); 3 partial remission (14%); 4 complete remission (18%), 2 pTo after complete transurethral resection (9%). These results lead us to conclude that: the rate of tumor progression and stability was too high. Further experience will require a more effective preoperative treatment; clinical staging dramatically underestimates tumor spread; prognosis of non responders is quite poor: 7 deaths with a maximum follow-up of 6 months.

Adult↗

[Treatment and course of advanced bladder cancers. Retrospective study of 29 cases].

A retrospective study of 29 patients with extensive but non metastatic bladder cancer (T234N+ M0) demonstrated once more the dreadful prognosis of advanced bladder cancer. Only 4 patients are alive without evidence of recurrence with a follow up of 12 to 64 months. The 11 patients whose tumor was too extended for radical cystectomy had a similar survival rate and better quality of survival than the 18 patients who underwent total cystectomy. Recurrence appears quickly (mean time : 11 months) and is mostly metastatic. This study led us to change our therapeutic attitude. We now use systemic preoperative polychemotherapy and we no longer perform radical cystectomy in bulky nodal metastasis.

Adult↗

Immune evaluation with skin tests in prostatic carcinoma.

By intradermal injection of 3 recall antigens, nonspecific secondary cell immunity was studied in 61 patients with prostatic carcinomas. Immune competence is lower in patients with metastatic disease. Skin tests have a short-term prognostical value.

Adult↗

Sequential polychemotherapy for advanced prostatic carcinoma. A preliminary cooperative study on 30 patients.

30 patients with advanced prostatic carcinomas received sequential polychemotherapy with association of vincristine (or VM 26), cyclophosphamide and 5-fluorouracil. In addition, 13 of these 30 patients received a dose of adriamycin during the first day of treatment, which did not change the results. This treatment was well tolerated and gave a good relief of bone pains.

Cyclophosphamide↗